Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
NCT02762084
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Basal Cell Nevus Syndrome
Interventions
DRUG:
Patidegib
DRUG:
Vehicle gel
Sponsor
PellePharm, Inc.